Toshio Takagi
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 336 publications
Editorial Comment to Feasibility and Safety of Repeat Robot-Assisted Partial Nephrectomy for Ipsilateral Local Recurrence: A Case Series.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: August 18, 2026
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.
Journal: JCO oncology practice
Published: June 03, 2026
Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Journal: Anticancer research
Published: May 18, 2026
Robot-assisted Complete Urinary Tract Exenteration for Multifocal Urothelial Carcinoma: Perioperative Management in Non-dialysis Patients.
Journal: Anticancer research
Published: April 27, 2026
Living-donor Kidney Transplantation After Resection of Mixed Epithelial and Stromal Tumor: A Positive Outcome Despite Not Observing the Recommended Waiting Period.
Journal: Cancer diagnosis & prognosis
Published: April 13, 2026
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.
Journal: Targeted oncology
Published: February 28, 2026
Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.
Journal: International urology and nephrology
Published: February 28, 2026
Belzutifan for Metastatic TFE3-Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report.
Journal: IJU case reports
Published: February 28, 2026
A kidney-protective mechanism via cellular oxidative stress reduction induced by CD5L protein.
Journal: Cell death discovery
Published: February 03, 2026
Pathologic Complete Response After Enfortumab Vedotin Plus Pembrolizumab in Node-positive Upper Tract Urothelial Carcinoma.
Journal: In vivo (Athens, Greece)
Published: January 20, 2026
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.
Journal: Japanese journal of clinical oncology
Published: January 11, 2026
Last Updated: 09/26/2026